A RANDOMIZED PHASE III DOUBLE BLINDED PLACEBO CONTROLLED TRIAL OF ASPIRIN AS ADJUVANT THERAPY FOR HER2 NEGATIVE BREAST CANCER: THE ABC TRIAL
The ABC Trial: Study of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer
Sponsor: National Cancer Institute
Enrolling: Male and Female Patients
IRB Number: AAAR7518
U.S. Govt. ID: NCT02927249
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: This randomized phase III trial studies how well aspirin works in preventing the cancer from coming back (recurrence) in patients with human epidermal growth factor receptor 2 (HER2) breast cancer after chemotherapy, surgery, and/or radiation therapy. Aspirin is a drug that reduces pain, fever, inflammation, and blood clotting. It is also being studied in cancer prevention. Giving aspirin may reduce the rate of cancer recurrence in patients with breast cancer.
This study is closed
Investigator
Dawn Hershman, MD
Do You Qualify?
Are you between the ages of 18 and 70? Yes No
Do you have node positive, HER2 negative, Stage II or III breast cancer and high risk node negative? Yes No
Are you within one year of diagnosis and recurrence free? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE